What happens to stocks if AI loses momentum?
MELVILLE, N.Y. -On Thursday, Henry Schein Inc. (NASDAQ:HSIC) reported fourth-quarter earnings and revenue that fell short of analyst expectations, while also providing full-year guidance below consensus estimates.
The company’s shares were down -1.4% in early trading following the announcement.
The healthcare products and services distributor posted adjusted earnings per share of $1.19 for the quarter ended December 28, missing the analyst consensus of $1.23. Revenue came in at $3.19 billion, below Wall Street’s forecast of $3.35 billion.
For the full year 2024, Henry Schein reported revenue of $12.7 billion, up 2.7% compared to 2023. The company said this reflected a 0.4% internal sales decrease, 3.3% growth from acquisitions, and a 0.2% decline from foreign currency exchange impacts.
Looking ahead, Henry Schein provided 2025 adjusted EPS guidance of $4.80 to $4.94, below the $4.97 analysts were expecting. The company projects total sales growth of 2% to 4% for 2025 compared to 2024 levels.
"Our fourth quarter financial results reflect relatively stable dental and medical end-markets," said Stanley M. Bergman, Chairman of the Board and CEO. "We continued to make progress on our 2022 to 2024 BOLD+1 Strategic Plan which we recently completed, exceeding our 2024 target of generating 40% of our worldwide operating income from high-growth, high-margin businesses."
The company said it expects 2025 to be the base year from which to grow and achieve its previously provided long-term goal of high-single digit to low-double digit earnings growth.
Henry Schein also announced a new organizational structure and reportable segments to provide more meaningful information for investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.